Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19941816 
Ji H, et al. (2009) EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 36, 547-59 19941816
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T360-p - CK2A1 (human)
Orthologous residues
CK2A1 (human): T360‑p, CK2A1 (mouse): T360‑p, CK2A1 (rat): T360‑p, CK2A1 (rabbit): T360‑p, CK2A1 (cow): T360‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) co-immunoprecipitation, activation of upstream enzyme, mutation in upstream enzyme recognition motif
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S362-p - CK2A1 (human)
Orthologous residues
CK2A1 (human): S362‑p, CK2A1 (mouse): S362‑p, CK2A1 (rat): S362‑p, CK2A1 (rabbit): S362‑p, CK2A1 (cow): S362‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) co-immunoprecipitation, activation of upstream enzyme, mutation in upstream enzyme recognition motif
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S641-p - CTNNA1 (human)
Orthologous residues
CTNNA1 (human): S641‑p, CTNNA1 (mouse): S641‑p, CTNNA1 (rat): S643‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), A431 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE CK2A1 (human)
 Comments:  ERK2 enhanced CK2-A1 phosphorylation of CTNNA1.
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, mutation in upstream enzyme recognition motif, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
TBB EGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  carcinogenesis, induced, cell motility, altered, transcription, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
CTNNB1 (human) Disrupts intracellular localization co-immunoprecipitation
 Comments:  S641 phosphorylation promotes Beta-catenin transactivation and tumor cell invasion.
Associated Diseases
Diseases: Alterations: Comments:
glioblastoma multiforme decreased

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), U373 MG (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
TBB EGF no effect upon treatment-induced increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), U373 MG (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
TBB EGF no effect upon treatment-induced increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), U373 MG (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
TBB EGF no effect upon treatment-induced increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), U373 MG (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
TBB EGF no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.